Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03597321

Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML (ELIT-AML01)

Comparative Phase II Trial of Early Prophylactic Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Myeloid Leukemia

Sponsor: Institut Paoli-Calmettes

Conditions Acute Myeloid Leukemia

Interventions prophylactic donor lymphocyte infusion (DLI)

Updated 7 times since 2018 Last updated: Jun 13, 2025 Started: Sep 7, 2020 Primary completion: May 31, 2027 Completion: May 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Myeloid Leukemia and is currently ongoing. Institut Paoli-Calmettes leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Jul 2025 — Present [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Nov 2024 — Jul 2025 [monthly]

Recruiting PHASE2

Status: Unknown → Recruiting
Sep 2024 — Nov 2024 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Feb 2024 [monthly]

Not Yet Recruiting PHASE2
Aug 2018 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Paoli-Calmettes

Data source: Institut Paoli-Calmettes

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Marseille, France